Publication date: Sep 16, 2025
Background: The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. This systematic review and meta-analysis aimed to determine the efficacy of nanocurcumin on mortality in patients with COVID-19. Methods: A systematic search was performed in PubMed, Embase, Cochrane Library, and clinicaltrials. gov up to November 2024, without language restrictions. Inclusion criteria: (1) inclusion of hospitalized patients with COVID-19 who are 18 years or older; (2) polymerase chain reaction positive for severe acute respiratory syndrome coronavirus-2; and (3) use of a randomized controlled design to make a comparison of nanocurcumin with placebo. The Cochrane risk-of-bias tool for randomized trials was used to assess the risk of bias. Studies were pooled to risk ratios (RRs) and standardized mean differences (SMDs), with 95% confidence intervals (CIs). Results: Six trials (enrolling 333 participants) met the inclusion criteria. Nanocurcumin therapy showed significant improvements on mortality (RR 0. 47, 95% CI 0. 25-0. 88; p = 0. 02), interleukin-6 (IL-6) (SMD -0. 30, 95% CI -0. 56 to -0. 04; p = 0. 02), tumor necrosis factor-α (TNF-α) (SMD -0. 63, 95% CI -1. 16 to -0. 10; p = 0. 02), and IL-1β (SMD -0. 88, 95% CI -1. 37 to -0. 39; p = 0. 0004). Conclusions: Nanocurcumin significantly reduced mortality, IL-6, TNF-α, and IL-1β in hospitalized patients with COVID-19. Given the lack of safety data and concerns about the risk of bias, the use of nanocurcumin in COVID-19 requires further research.
| Concepts | Keywords |
|---|---|
| Coronavirus | COVID-19 |
| Death | meta-analysis |
| Therapy | mortality |
| nanocurcumin |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| pathway | KEGG | Coronavirus disease |
| disease | MESH | death |
| drug | DRUGBANK | Methionine |
| disease | MESH | Long Covid |